 Home > Medical News > Medicines Company News > Numai Medical completes more than 100 million U.S. dollars in Series C financing to accelerate the research and development of structural heart disease interventional products

Numai Medical completes more than 100 million U.S. dollars in Series C financing to accelerate the research and development of structural heart disease interventional products

 Last Update: 2021-07-14
 Source: Internet
 Author: User

Tags

bone growth disease

quarterly financial report

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In response to the domestic technological gap, NewMedical has developed the TMVR product Mi-thos, which has been approved to enter the national special review procedure for innovative medical devices and is expected to become the first approved TMVR innovative product in China

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.